Innate Pharma

Equities

IPH

FR0010331421

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:35:09 2024-06-14 EDT			5-day change	1st Jan Change
2.125 ^EUR	-3.63%		-16.17%	-18.89%

06-11	Transcript : Innate Pharma S.A. - Special Call
06-04	Innate Pharma: positive data in mycosis fungoides	CF

Innate Pharma: five abstracts selected for ASCO

May 24, 2024 at 08:06 am

Innate Pharma announces that five abstracts concerning its drug candidates have been selected for the annual meeting of the American Society of Clinical Oncology (ASCO), to be held from May 31 to June 4 in Chicago, USA.

One poster will present final data from the TELLOMAK Phase 2 trial in mycosis fungoides, confirming lacutamab's promising clinical activity, while two others will focus on IPH6501 for the treatment of non-Hodgkin's B lymphoma.

Two other posters, presented by partner AstraZeneca, will focus on phase 2 trials with monalizumab in non-operable stage III non-small cell lung cancer and small cell lung cancer.

Copyright (c) 2024 CercleFinance.com. All rights reserved.

Go to the original article.
Legal disclaimer

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	ASTRAZENECA PLC	12,510 GBX	+0.95%	-0.37%	246B
	INNATE PHARMA	2.125 EUR	-3.63%	-16.17%	184M

Latest news about Innate Pharma

Transcript : Innate Pharma S.A. - Special Call	06-11
Innate Pharma: positive data in mycosis fungoides	06-04	CF
Innate Pharma SA Presents Positive Results from TELLOMAK Phase 2 Study with Lacutamab in Mycosis Fungoides	06-04	CI
Innate Pharma: five abstracts selected for ASCO	05-24	CF
Transcript : Innate Pharma S.A., Q1 2024 Earnings Call, May 14, 2024	05-14
Sanofi: progress in hematology trial	04-15	CF
Innate Pharma: progress in hematology trial	04-15	CF
Innate Pharma Announces Advancement of Sanofi-Developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients	04-15	CI
Innate Pharma: IPH45 data presented at AACR	04-10	CF
Innate Pharma S.A. Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate	04-10	CI
Transcript : Innate Pharma S.A., 2023 Earnings Call, Mar 21, 2024	03-21
Innate Pharma S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
Innate Pharma initiates lymphoma trial	03-06	CF
Innate Pharma: abstract on IPH45 at the AACR congress	03-06	CF
Innate Pharma S.A. Announces First Patient Dosed in Phase 1/2 Study of IPH6501 in Relapsed /Refractory B-Cell Non-Hodgkin?s Lymphoma	03-06	CI
Global markets live: Next, Shell, GM, Apple, Nasdaq...	01-04
US FDA Ends Partial Clinical Hold on Innate Pharma's Investigational Cancer Drug	01-04	MT
Innate Pharma Says FDA Lifted Partial Clinical Hold on Lacutamab Clinical Program	01-04	MT
Innate Pharma: FDA suspension lifted	01-04	CF
Innate Pharma appoints two new board members	01-04	CF
Innate Pharma S.A. Announces Executive Changes	01-04	CI
Sector Update: Health Care Stocks Gain Premarket Tuesday	12-19	MT
Innate Pharma Shares Rise after Sanofi Exercises Licensing Option	12-19	DJ
Innate Pharma S.A. and Sanofi Announce Licensing of Fourth Natural Killer Cell Engager in Oncology to Sanofi	12-19	CI
Sanofi Exercises Option to License 4th NK Cell Engager Program in Solid Tumors From Innate Pharma's ANKET Platform	12-19	MT

Chart Innate Pharma

Duration

Period

More charts

Company Profile

Innate Pharma is a clinical-stage biotechnology company specialized in immuno-oncology and dedicated to improving cancer treatment through innovative therapeutic antibodies that exploit the immune system. Innate Pharma's broad antibody portfolio includes several potential «first-in-class» candidates in clinical and preclinical stages in cancers with high medical need. Innate Pharma is a pioneer in the understanding of NK cell biology and has developed expertise in the tumor microenvironment and tumor antigens, as well as in antibody engineering. Its innovative approach has enabled it to build a diversified proprietary portfolio and to forge alliances with leading biopharmaceutical companies such as Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi as well as a multi-product partnership with AstraZeneca. Revenues break down by source of income as follows: - revenues from collaboration and licensing agreements (84.2%); - government financing for research expenditure (15.8%). At the end of 2023, the company had a portfolio of 7 products in clinical development, including 1 in phase III (Monalizumab for the treatment of cancer), 2 in phase II (Lacutamab for the treatment of cutaneous T-cell lymphomas and IPH5201 for the treatment of cancer) and 4 in phase I (IPH5301 for the treatment of solid tumours, IPH6101 for the treatment of relapsed or refractory acute myeloid leukaemia, IPH6401 for the treatment of multiple myeloma and IPH6501 for the treatment of non-Hodgkin lymphoma).

Sector

Biotechnology & Medical Research

Calendar

2024-06-24 - H.C Wainwright Immune Cell Engager Virtual Conference

More about the company

Income Statement Evolution

More financial data

Ratings for Innate Pharma

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.125 EUR

Average target price

6.475 EUR

Spread / Average Target

+204.71%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
INNATE PHARMA	-18.89%	184M
MODERNA, INC.	+40.80%	53.67B
LONZA GROUP AG	+35.79%	38.86B
IQVIA HOLDINGS INC.	-8.05%	38.76B
CELLTRION, INC.	-8.98%	27.27B
ICON PUBLIC LIMITED COMPANY	+10.69%	25.91B
ALNYLAM PHARMACEUTICALS, INC.	-16.21%	20.29B
UNITED THERAPEUTICS CORPORATION	+31.00%	12.78B
MEDPACE HOLDINGS, INC.	+28.51%	12.18B
BIO-TECHNE CORPORATION	-1.67%	11.96B

Other Biotechnology & Medical Research